Cargando…
One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
PURPOSE: To compare the 1-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy (RF-PDT) to intravitreal ranibizumab (IVR) alone for eyes with polypoidal choroidal vasculopathy (PCV). METHODS: We reviewed the medical records from 47 consecutive patients with PCV...
Autores principales: | Sakurai, Madoka, Baba, Takayuki, Kitahashi, Masayasu, Yokouchi, Hirotaka, Kubota-Taniai, Mariko, Bikbova, Guzel, Oshitari, Toshiyuki, Yamamoto, Shuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913546/ https://www.ncbi.nlm.nih.gov/pubmed/24511222 http://dx.doi.org/10.2147/OPTH.S54578 |
Ejemplares similares
-
Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy
por: Kitahashi, Masayasu, et al.
Publicado: (2014) -
Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: Short-term results
por: Mitamura, Yoshinori, et al.
Publicado: (2010) -
Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
por: Sonoda, Shozo, et al.
Publicado: (2013) -
Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy
por: Ngo, Wei Kiong, et al.
Publicado: (2020) -
Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)